National data shows COVID-19 levels are moderate. In most of the U.S., levels of other respiratory viruses are low, although RSV is ticking up in some southeastern states.
The Food and Drug Administration has approved the first vaccine for expectant mothers to shield their babies from RSV.
At least 58,000 childern younger than 5 years old are hospitalized each year with RSV infections. A Pfizer vaccine given to pregnant people could help protect their infants from severe RSV illness.